Soleno Therapeutics, Inc. (SLNO) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Redwood City, CA, 미국. 현재 CEO는 Anish Bhatnagar.
SLNO 을(를) 보유 IPO 날짜 2014-11-13, 115 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $2.72B.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
